Acquired resistance to doxorubicin significantly reduces its therapeutic efficacy, limiting its clinical use in breast cancer treatment. Pan-AKR1C inhibitors have demonstrated potential in restoring ...

NS-229, an investigational selective Janus kinase 1 (JAK1) inhibitor developed by NS Pharma, has received Orphan Drug Designation from the US Food & Drug Administration (FDA) for the treatment of ...

The Food and Drug Administration (FDA ... NS-229 is an investigational selective Janus kinase 1 (JAK1) inhibitor designed to prevent tissue damage caused by EGPA by suppressing immune cell ...

accepted a New Drug Application (NDA) for its new generation pan-TRK inhibitor zurletrectinib (ICP-723) for the treatment of adult and adolescent patients (12 to 18 years old) with advanced solid ...

The hybrid proteins retained the structure of the neuraminidase scaffold and the antigenicity ... four Beta strands and the Loops 12 and 34 we refer to as the “scaffold”. Oseltamivir is shown in red ...

Targeted populations As strain-specific vaccine is available, target high-priority groups (500 million out of a world population of 6.5 billion); should include essential personnel, health care ...

Most of the pre-existing NSAIDs inhibited both isoforms, perhaps explaining why these drugs had both therapeutic and side effects. An intensive search was begun to find a selective COX2 inhibitor.

Therapeutic drug monitoring (TDM) is uncommon in child and adolescent psychiatry, particularly for selective serotonin reuptake inhibitors (SSRIs)—the first-line pharmacologic treatments for ...

Children should not be given the anti-viral drug Tamiflu to combat swine flu, Oxford University researchers have said. They urged the United Kingdom Department of Health to urgently rethink its ...

Disclosure: Patrick H. Peters, Jr, MD, has disclosed that he is a consultant to Roche, sanofi-aventis, and Pfizer, and has received research grants from Roche, Merck and Co., Pfizer, sanofi ...